Biyu daga cikin nunin faifai da farfesa a fannin ilmin sinadarai na Jamus Gerald Dyker da Jörg Matysik suka yi amfani da su a cikin su. yanzu shahararriyar hira A kan nau'in guba daban-daban na allurar Pfizer-BioNTech an gani a duk duniya: (1) jadawali daga binciken Danish, yana nuna bambance-bambance masu yawa a cikin guba tsakanin 'blue,' 'kore,' da 'rawaya' batches, da (2) teburin nasu yana nuna kusan ginshiƙi na 'nein,' wanda ke nuna cewa mai kula da aikin, Cibiyar Paul Ehrlich ta Jamus (PEI), ba ta ƙaddamar da batches 'rawaya' da alama mara lahani ga gwajin sarrafa inganci.
Binciken na ƙarshe ne - kuma ba binciken Danish mai zafi da aka yi muhawara akai-akai ba - wanda ya jagoranci Farfesa Dyker ya kammala cewa batches na rawaya na iya zama 'wani abu kamar placebos,' bayan haka. Amma zane na uku daga cikin hirar kuma ya cancanci a san shi sosai, tunda ya sake mai da hankali kan wani muhimmin al'amari na wannan labarin wanda kusan ya ɓace gaba ɗaya a cikin sauti da fushin ƙoƙarin "debunkings" na hasashen placebo: wato, dangantakar da ke tsakanin mai gudanarwa, Cibiyar Paul Ehrlich, da masana'anta, BioNTech na Jamus.
Don bayyana a bayyane - kuma wannan shine ainihin abin da Farfesa Dyker ke yi a cikin maganganun da ake zaton masu tayar da hankali a cikin hira - lura da cewa mai kula da shi bai gwada daidai ba a fili batches marasa lahani yana nuna rashin dacewa: kamar dai ya sani a gaba cewa batches ba su da lahani kuma don haka ba ya buƙatar kula da inganci. Yana ba da shawarar cewa PEI ya haɗa kai tare da masana'anta don sanya samfurin da aka lalata - ƙila a cikin wannan yanayin, samfuri mai ƙima - akan kasuwa.
Ya kamata a jaddada cewa masana'anta a nan shi ne ainihin kamfanin Jamus BioNTech. BioNTech, ba sanannen abokin tarayya na Amurka Pfizer ba, shine bisa doka ya kera abin da ake kira allurar Pfizer-BioNTech. Pfizer dan kwangila ne wanda ke gudanar da (wasu) ayyukan masana'antu a madadin BioNTech. Ana nuna wannan a koyaushe akan alamar rigakafin. (Duba ƙasa, alal misali, kuma, don ƙarin misalai da tattaunawa, nan).
Yana da mahimmanci a lura cewa a cikin EU, BioNTech shima yana ba da gudummawa kai tsaye ga sarkar samar da kayayyaki ta hanyar kera sinadarin magani mai aiki, watau mRNA, a cikin nasa kayan aikin.
Bugu da ƙari, BioNTech, ba Pfizer ba, shine mai ba da izinin tallan don rigakafin a cikin EU, kamar a yawancin kasuwanni. Don haka, kamfanin na Jamus BioNTech ne ke da alhakin samar da samfurori ga jami'in gudanarwa na Jamus, Cibiyar Paul Ehrlich, kamar yadda hirar Dyker da Matysik ta bayyana.
Bari mu yi dubi yanzu a kan faifan farfesa na uku a kasa. Ya kamata a tuna cewa Dyker da Matysik wani bangare ne na rukunin masana kimiyya guda biyar masu magana da Jamusanci waɗanda ke tada tambayoyi game da inganci da amincin rigakafin BioNTech tare da masana'anta da PEI.
Zauren ya ƙunshi kawai tweet mai kwanan wata Yuni 6th. Marubucin da tweet ba kowa bane illa Ministan Lafiya na Jamus Karl Lauterbach. Hoton ya nuna Lauterbach a Cibiyar Paul Ehrlich tare da shugaban PEI Klaus Cichutek da wasu ma'aikatan lab. Lauterbach shine mutumin a tsakiyar hoton kuma Cichutek yana hannun dama.
Rubutun ya kasance kamar haka:
A yau, na ziyarci Cibiyar Paul Ehrlich. Farfesa Klaus Cichutek da ni muna cikin dakin da aka gwada ingancin maganin BioNTech. Idan ba tare da PEI ba, da an ba da izinin rigakafi da yawa daga baya. Duk da haka, ba a sami raguwa a kan aminci ba. Na gode PEI!
In hirar, Farfesa Dyker ya bayyana damuwarsa da takwarorinsa game da ikirarin Lauterbach cewa an gwada ingancin maganin rigakafi na BioNTech a PEI: 'Ba mu taɓa jin akwai wani nau'in gwajin sauri na tasirin maganin alurar riga kafi ba,' in ji shi, 'A al'ada, ana gwada shi a cikin gwaji na asibiti, bayan duk.
Amma, fiye da kai tsaye, ya kuma lura cewa hoton bangon bayan Lauterbach da Cichutek a cikin hoton ana yiwa taken 'Sakin Batch na Alurar rigakafin Covid-19: Labarin Nasara' - kamar yarda da batches don sakin su ne manufar PEI da burin. Ganin babban matakin mummunan al'amuran da ke da alaƙa da batches shuɗi a cikin binciken Danish, duk wanda Cibiyar Paul Ehrlich ta amince da sakin su, bayanin sakin su a matsayin 'labarin nasara' abin tambaya ne, a takaice.
Haka kuma, sharhin Lauterbach cewa 'Ba tare da PEI ba, da an ba da izinin alluran rigakafi da yawa daga baya' ya jefa PEI a daidai wannan rawar. mai kunnawa maimakon mai tsarawa - ko da ya yi gaggawar ƙara cewa 'Duk da haka, babu wata matsala a kan aminci.'
Lauterbach yayi daidai. Idan ba tare da PEI ba, izinin Pfizer-BioNTech rigakafin zai ɗauki lokaci mai tsawo. Amma a gaskiya mun san cewa akwai ya daidai da daidaitawa kan aminci: ba kawai saboda munanan bayanan aminci da ke da alaƙa da shuɗi na allurar rigakafin - wanda, watakila ba kwatsam ba, ya bayyana a matsayin farkon batches da aka saki a cikin EU - amma kuma saboda gajerun hanyoyin da BioNTech ya ɗauka tare da albarkar PEI lamari ne na rikodin jama'a.
Don haka, a cikin wani tsari da ba a saba gani ba, PEI ta ƙyale BioNTech ta fara gwajin asibiti (watau ɗan adam) na ƴan takarar rigakafin cutar ta Covid-19 kafin ma an kammala nazarin ilimin toxicology na dabbobi, dangane da sakamakon wucin gadi kawai. An rubuta cikakkun bayanai game da wannan tsari a cikin labarina nan. Kamar yadda aka tattauna a waccan labarin, wasu nau'ikan ƙarin gwaje-gwaje na yau da kullun, waɗanda ake kira nazarin ilimin harhada magunguna, kawai an tsallake su gaba ɗaya.
Ya kamata a lura cewa BioNTech da PEI sun ɗauki waɗannan yanke shawara ba tare da sa hannun Pfizer ba, kamfanin Amurka ya shiga aikin rigakafin BioNTech ne kawai don tsarin aikin ba da izini.
Idan aka yi la’akari da irin gagarumin mahimmancin tattalin arziki da nasarar BioNTech ta samu ga tattalin arzikin Jamus, ana iya yin mamaki gabaɗaya game da hikimar da ke tattare da samun mai kula da harkokin Jamus a matsayin mai kula da fitar da rukunoni ga dukkan ƙasashe membobin EU. Rikici mai yuwuwa na sha'awa a bayyane yake. Yunƙurin mercurial na BioNTech shine, alal misali, ainihin motsin dawowar Jamus don haɓakawa a cikin 2021 (kamar yadda aka taɓa shi. nan), don a ce komai na kusan kashi 30 na ribar da kamfani ke biya a harajin kamfanoni.
Amma irin wannan shakku ya fi dacewa idan muka yi la'akari da cewa PEI tana da daɗaɗɗen dangantaka da waɗanda suka kafa BioNTech Ugur Sahin da Özlem Türeci, wanda, ba tare da tsayin daka ba, ya kasance mai kusanci da haɗin gwiwa. An yarda da wannan a fili Alurar rigakafin, asusun auto-hagiographical na ci gaban rigakafin BioNTech wanda Sahin da Türeci suka rubuta tare da ɗan jarida Joe Miller.
Don haka, a p. 45 na Alurar rigakafin, mun gano cewa ma'aikatan PEI:
har ma da haɗin gwiwar takaddun kimiyya tare da majagaba na mRNA, gami da Ugur da Özlem. Ma'auratan sun halarci "bincike na bincike" wanda mai gudanarwa ya shirya - ainihin tarurruka a lokacin da aka tattauna iyakokin binciken likita daki-daki. Masu ƙirƙira da masu gudanarwa sun koya game da sabbin fasahohin zamani, kamar mRNA, tare.
Amma ba wai kawai PEI ba ne ma'aikatan suna da takaddun haɗin gwiwa tare da Sahin da Türeci. Kamar yadda ake iya gani a ƙasa, shugaban PEI Cichutek yana da kansa tare da haɗin gwiwa takarda - Abin sha'awa sosai, akan haɓaka rigakafin Coronavirus! - ba tare da kowa ba face Shugaban Kamfanin BioNTech Ugur Sahin.
Baya ga kasancewa shugaban PEI, haka kuma, Cichutek, kamar yadda ake iya gani nan, Har ila yau, "Mai Gudanar da Ci Gaban Samfura" a Cibiyar Nazarin Cutar Cutar ta Jamus (DZIF).
Abokan hulɗa na waje na DZIF ba su haɗa da kowa ba face BioNTech. Gidan yanar gizon DZIF bayanin kula cewa:
Tare da haɗin gwiwa tare da BioNTech da Cibiyar binciken ilimin halittu ta Fassarar Oncology a Jami'ar Mainz (TRON), DZIF tana binciken alluran rigakafin RNA don zaɓaɓɓun iyalai masu cutar da ƙwayoyin cuta masu yuwuwar ɗan adam, kuma daga baya ya kawo su cikin ci gaban asibiti da farko.
TRON, kamar BioNTech, Ugur Sahin da Özlem Türeci ne suka kafa shi.
Tabbas, PEI koyaushe na iya share duk wasu zarge-zargen da ke rataye a kai saboda rashin ingancin kula da batches na rawaya da alama ba su da lahani na rigakafin Pfizer-BioNTech. Wataƙila akwai, bayan duk, wani bayani marar laifi.
Amma a cikin hirar Dyker da Matysik, Farfesa Matysik ya lura cewa sadarwa ta ƙarshe da farfesa suka samu daga PEI sanarwar ce ta hukuma cewa ba za su sami ƙarin amsa ga tambayoyinsu ba.
(Fassara daga Jamusanci ta marubucin, lokacin da babu shi a tushen da aka haɗa.)
-
Robert Kogon shi ne sunan alkalami na wani ɗan jarida da ake bugawa da yawa wanda ke yin rubuce-rubuce kan al'amuran Turai.
Duba dukkan posts
